Skip to main content

Table 1 Demographic and clinical characteristics of FMT–HVD patient samples used for validation of the HIV/HCV/HBV/Malaria NAT assay

From: Use of a NAT-based assay to improve the surveillance system and prevent transfusion-transmitted malaria in blood banks

Patient Source Gender Age Parasitaemia (parasites/µL) Asexual parasitaemia (parasites/µL)
Asexual Sexual Rings Trophozoites Schizonts
1 FMT–HVD F 26 5757.6 242.4 666.6 5091 0
2 FMT–HVD M 43 5355.2 644.8 2221 3080.6 53.7
3 FMT–HVD M 35 6000 0 3060 2940 0
4 FMT–HVD M 21 6100 0 3468 2632.3 0
5 FMT–HVD M 37 5861.7 138.3 1078 4783.4 0
6 FMT–HVD M 20 5847.6 152.4 4476 1352.4 19
7 FMT–HVD M 35 6000 0 5040 960 0
8 FMT–HVD F 40 6000 0 0 6000 0
9 FMT–HVD M 29 5841.7 158.3 1285 4504.4 52.8
10 FMT–HVD F 32 6000 0 0 6000 0
11 FMT–HVD M 49 6000 0 4254 1746.5 0
12 FMT–HVD M 36 4610.7 1389.3 3785 805.4 20.1
13 FMT–HVD M 17 6000 0 5345 655.2 0
14 FMT–HVD F 21 6000 0 3558 2441.9 0
15 FMT–HVD F 34 6000 0 1774 4226.1 0
16 FMT–HVD M 34 5613.4 386.6 2799 2814.4 0